Rate Video

EAN 2020 | BIPARK-I and II: opicapone and levodopa in PD with motor fluctuations

Angelo Antonini • 20 May 2020

EAN 2020

Movement Disorders Parkinson's Disease Levodopa Opicapone

BIPARK-I BIPARK-II Treatment Trial Updates

Angelo Antonini, MD, PhD, University of Padua, Padua, Italy, discusses a post-hoc analysis of the BIPARK-I and BIPARK-II trials. The results confirm that using a catechol-O-methyltransferase (COMT) inhibitor, such as opicapone, can significantly extend the benefits of levodopa in Parkinson’s disease (PD) patients with motor fluctuations. This interview was recorded during an online conference call with The Video Journal of Neurology (VJNeurology).

Increasing mobility in patients with Parkinson’s disease during COVID-19

Angelo Antonini • 29 Mar 2022

Wearables: technological advancements in movement disorder management

Angelo Antonini • 1 Jul 2023

Adjunctive MAO-B or COMT inhibitors to optimize levodopa treatment in PD

Angelo Antonini • 26 Jun 2022

Subcutaneous 24-hour infusion of foslevodopa/foscarbidopa improves motor symptoms in PD patients

Angelo Antonini • 27 Aug 2023

Related Videos

Recent developments in cell replacement therapy for Parkinson’s disease

Alfonso Fasano • 19 Oct 2023

Regenerative medicine-based approaches in Parkinson’s disease

Alfonso Fasano • 19 Oct 2023

Functional electrical stimulation: beyond stroke

Rosalyn Grabarz • 12 Oct 2023

The future of neuromodulation in movement disorders

Alfonso Fasano • 7 Sep 2023